Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
13.05
+0.15 (1.16%)
May 14, 2025, 1:27 PM CST

Mercury Biopharmaceutical Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
May '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Market Capitalization
5,4425,4987,7784,006--
Upgrade
Market Cap Growth
-29.32%-29.32%94.15%---
Upgrade
Enterprise Value
5,2595,2757,4653,937--
Upgrade
Last Close Price
12.9013.0518.709.87--
Upgrade
PS Ratio
1096.481107.827530.001494.92--
Upgrade
PB Ratio
18.7518.9420.0322.22--
Upgrade
P/TBV Ratio
19.0419.2420.1722.28--
Upgrade
EV/Sales Ratio
-1062.907226.331469.06--
Upgrade
Debt / Equity Ratio
0.160.160.110.240.19-1.43
Upgrade
Asset Turnover
0.010.010.000.02--
Upgrade
Quick Ratio
12.0312.0340.8919.791.500.28
Upgrade
Current Ratio
12.6312.6342.2120.152.300.32
Upgrade
Return on Equity (ROE)
-14.90%-14.90%-15.41%-32.76%-103.62%-
Upgrade
Return on Assets (ROA)
-8.54%-8.54%-8.55%-15.87%-49.15%-103.35%
Upgrade
Return on Capital (ROIC)
-8.79%-8.79%-8.73%-16.35%-52.74%-108.47%
Upgrade
Earnings Yield
-0.93%-0.92%-0.56%-0.78%--
Upgrade
FCF Yield
-0.82%-0.81%-0.71%-2.35%--
Upgrade
Buyback Yield / Dilution
-5.79%-5.79%-5.83%-36.09%-165.94%-
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.